CHMP Backs Repatha for First Heart Attack/Stroke Prevention, Expanding Blockbuster's Reach
AMGN sits 46% above its 52-week low of $269.77.
Summary
The CHMP positive opinion supports expanding Repatha's label to include high-risk adults without a prior heart attack or stroke, based on the VESALIUS-CV trial showing a 25% reduction in major cardiovascular events. This opens a large new patient population in Europe, where many high-risk individuals fail to reach LDL-C targets on statins alone. Repatha is already a key growth driver for Amgen, and broader use could significantly boost sales. The European Commission typically follows CHMP opinions, with a final decision expected in the coming months. This comes amid recent setbacks for Amgen's Tavneos, making Repatha's success even more critical for the pipeline.
At the time of this announcement, AMGN was trading at $393.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.2B. The 52-week trading range was $269.77 to $398.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.